This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Recurrent stroke accounts for substantial morbidity and mortality among ischemic stroke survivors. To establish effective treatments for secondary stroke prevention, it is important to determine factors associated with stroke recurrence. Among the blood biomarkers associated with stroke risk, lipoprotein-associated phospholipase A2 (LpPLA2) is perhaps the most studied. LpPLA2 hydrolyzes oxidized phospholipids and plays an important role in atherosclerosis, with elevated plasma levels associated with increased risk of ischemic stroke and myocardial infarction. Other markers associated with stroke risk include fibrinogen, C-reactive protein, d-dimer, total homocysteine, and l-arginine.1,2 Such markers can aid in stroke risk stratification and potentially provide therapeutic targets to prevent stroke. Indeed, ongoing trials are evaluating whether inhibiting LpPLA2 with darapladib can reduce cardiovascular events.
Footnotes
Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the editorial.
See page 1142
- © 2014 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Topics Discussed
Alert Me
Recommended articles
High free fatty acid level is associated with recurrent stroke in cardioembolic stroke patients
Racial differences in recurrent ischemic stroke risk and recurrent stroke case fatality
White matter hyperintensity load on stroke recurrence and mortality at 1 year after ischemic stroke
Total small vessel disease score and risk of recurrent stroke